Mumbai, July 13, 2021: Tatva Chintan Pharma Chem Limited (“Company”), a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents, phase transfer catalysts, electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals, is proposing to open its initial public offering of Equity Shares (“Offer”) on July 16, 2021.

The price band of the Offer has been fixed at ₹1,073 to ₹ 1,083 per Equity Share. Bids can be made for a minimum of 13 Equity Shares and in multiples of 13 Equity Shares thereafter.

The Offer comprises of a fresh issue of such number of Equity Shares aggregating up to ₹2,250.00 million and an offer for sale of up to aggregating up to ₹2,750.00 million, with a sale of such number of Equity Shares Equity Shares aggregating up to ₹233.00 million by Ajaykumar Mansukhlal Patel, such number of Equity Shares aggregating up to ₹814.00 million by Chintan Nitinkumar Shah, and up to ₹730.00 million by Shekhar Rasiklal Somani, and up to ₹103.00 million by Darshana Nitinkumar Shah, up to ₹342.00 million by Priti Ajaykumar Patel, up to ₹342.00 million by Ajay Mansukhlal Patel HUF, up to ₹110.00 million by Kajal Shekhar Somani, up to ₹11.00 million by Shitalkumar Rasiklal Somani, and up to ₹65.00 million by Samirkumar Rasiklal Somani.

This Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”). This Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that the Company in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price. 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA Account, which will be blocked by the Self Certified Syndicate Banks, or through the UPI Mechanism. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA Process. For details, see the section titled “Offer Procedure” of the RHP on page 312 of the RHP.

The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on BSE and NSE.

ICICI Securities Limited and JM Financial Limited are the book running lead managers (“BRLMs”) to the Offer.